Simulations Plus (NASDAQ:SLP) Updates FY25 Earnings Guidance

Simulations Plus (NASDAQ:SLP) issued an update on its FY25 earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of $1.07-1.20 for the period, compared to the consensus earnings per share estimate of $1.09. The company issued revenue guidance of $90-93 million, compared to the consensus revenue estimate of $90.40 million. Simulations Plus also updated its FY 2025 guidance to 1.070-1.200 EPS.

Analysts Set New Price Targets

Several analysts have recently commented on SLP shares. William Blair reiterated an “outperform” rating on shares of Simulations Plus in a research report on Wednesday, January 8th. KeyCorp raised their price target on Simulations Plus from $35.00 to $37.00 and gave the stock an “overweight” rating in a research report on Friday, January 24th. One analyst has rated the stock with a sell rating, one has issued a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Simulations Plus presently has an average rating of “Moderate Buy” and a consensus price target of $49.40.

Simulations Plus Stock Performance

Shares of SLP opened at $23.82 on Friday. Simulations Plus has a fifty-two week low of $23.00 and a fifty-two week high of $51.22. The stock has a fifty day moving average of $30.19 and a two-hundred day moving average of $30.33. The company has a market capitalization of $478.59 million, a PE ratio of 59.55 and a beta of 0.89.

Simulations Plus (NASDAQ:SLP) last released its earnings results on Thursday, April 3rd. The technology company reported $0.31 EPS for the quarter, beating the consensus estimate of $0.25 by $0.06. Simulations Plus had a return on equity of 6.84% and a net margin of 10.97%. The firm had revenue of $22.43 million during the quarter, compared to analyst estimates of $21.93 million. During the same period in the prior year, the firm posted $0.20 earnings per share. The business’s quarterly revenue was up 22.5% compared to the same quarter last year. As a group, equities research analysts forecast that Simulations Plus will post 1.09 earnings per share for the current fiscal year.

Insider Transactions at Simulations Plus

In related news, Director Walter S. Woltosz sold 20,000 shares of the stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $33.91, for a total value of $678,200.00. Following the transaction, the director now directly owns 3,402,584 shares of the company’s stock, valued at approximately $115,381,623.44. This trade represents a 0.58 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders own 19.40% of the company’s stock.

Simulations Plus Company Profile

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.